Targeting immune evasion via immune checkpoint pathways has changed the treatment
paradigm in cancer. Since CTLA-4 antibody was first approved in 2011 for treatment of …

Non-small cell lung cancer (NSCLC) represents the most common and fatal type of primary
lung malignancies. NSCLC is often diagnosed at later stages and requires systemic …

Stage II–IIIA nonsmall cell lung cancer (NSCLC) patients receive adjuvant chemotherapy
after surgery as standard‐of‐care treatment, even though only approximately 5.8% of …

Introduction In recent years, immunotherapy has become a pillar in the treatment of
advanced, non-oncogene-addicted non-small cell lung cancer (NSCLC). Programmed …

Background: Patients with non-small cell lung cancer (NSCLC) presenting with
mesenchymal–epithelial transition (MET) exon 14 skipping mutation have an unfavorable …

Immune checkpoint inhibitors (ICIs) have achieved huge clinical success. However, many
still have limited response rates, and are prohibitively costly. There is a need for effective …

Therapies that modulate immune response to cancer, such as immune checkpoint inhibitors,
began an intense development a few years ago; however, in breast cancer (BC), the results …

Purpose Lung cancer relapse may be associated with the presence of a small population of
cancer stem cells (CSCs) with unlimited proliferative potential. Our study assessed the …

Background Neoadjuvant chemoimmunotherapy for resectable non-small cell lung cancer
(NSCLC) represents an important research topic. Despite the potential benefits of this …

Simple Summary Surgical resection remains the gold standard of early-stage non-small cell
lung cancer (NSCLC) treatment. However, only a minority of resected patients remain …